PAR-25-108-Full-Announcement.html

This document is a Notice of Funding Opportunity (NOFO) for the Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) grant program. The National Cancer Institute (NCI) is soliciting grant applications to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics, or diagnostics. The R21 funding mechanism is intended to support exploratory projects at an early conceptual stage to demonstrate the feasibility of the proposed approach. Eligible applicant types include higher education institutions, state/local governments, non-profits, small businesses, and others. The grant program is associated with the Cancer Treatment Research, Oral Diseases and Disorders Research, and Cancer Biology Research federal grant programs. The deadline for applications is not provided.